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Pharmacy-Drug Science, University of Bari, Aldo Moro, ItalyABSTRACT Previously identified potent and/or use-dependent mexiletine (Mex) analogs were used as template for the
rational design of new Nav-channel blockers. The effects of the novel analogs were tested on sodium currents of native myo-
fibers. Data and molecular modeling show that increasing basicity and optimal alkyl chain length enhance use-dependent block.
This was demonstrated by replacing the amino group with a more basic guanidine one while maintaining a proper distance
between positive charge and aromatic ring (Me13) or with homologs having the chirality center nearby the amino group or
the aromatic ring. Accordingly, a phenyl group on the asymmetric center in the homologated alkyl chain (Me12), leads to a further
increase of use-dependent behavior versus the phenyl Mex derivative Me4. A fluorine atom in paraposition and one ortho-methyl
group on the xylyloxy ring (Me15) increase potency and stereoselectivity versus Me4. Charge delocalization and greater flexi-
bility of Me15 may increase its affinity for Tyr residues influencing steric drug interaction with the primary Phe residue of the
binding site. Me12 and Me15 show limited selectivity against Nav-isoforms, possibly due to the highly conserved binding site
on Nav. To our knowledge, the new compounds are the most potent Mex-like Nav blockers obtained to date and deserve further
investigation.INTRODUCTIONVoltage-gated sodium channels are therapeutic targets in
a large spectrum of membrane hyperexcitability disorders,
including cardiac arrhythmias, epilepsies, chronic pain, and
myotonias (1,2). In particular, the skeletal muscle sodium
channel isoform, Nav1.4 is the molecular target of current
first-line therapies against myotonic syndromes. Lidocaine
(LA)-like drugs is widely used antimyotonic compounds
because they block Nav1.4 in a state- and use-dependent
manner. This blocking mechanism relies on the high-affinity
drug binding to the channel in its open or inactivated state,
and to a slow recovery from inactivation of the drug-
bound channel. These actions dampen membrane excitation
and prevent reexcitation during membrane repolarization
(3,4). However, LA-like compounds can cause undesirable
effects and this has led to the discontinuation of mexiletine
(Mex) in some countries. Therefore, there is a need for
Nav1.4 blocking drugs with greater tissue specificity.
A key factor limiting the further development of Nav1.4-
specific blocking compounds is the lack of more complete
structure-function information on the interactions of such
drugs with the channel. Many previous studies have sug-
gested that hydrophobic blocking drugs have a unique
access pathway to the channel pore, unlike the more hydro-Submitted May 25, 2012, and accepted for publication November 21, 2012.
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opening. Site-directed mutagenesis studies have identified
a cluster of highly conserved residues among the Nav
subtypes that are important for block by LA-like drugs.
These residues include DIVS6-Phe-1759 and DIVS6-Tyr-
1766, and DIIIS6-Leu-1461 (based on Nav1.5) (5–7). LA-
like drugs share a common structural backbone composed
of an aromatic ring and a protonable amino group linked
by a short alkyl chain. Docking studies of its interaction
with Nav1.4 depict a p-cation interaction of the charged
amino group with the aromatic ring of Phe-1759 in DIVS6,
reinforced by a further dock with nearby Leu-1461 on
DIIIS6. The nonpolar tail of LA-like drugs, i.e., the alkyl
chains and aromatic ring, participates in hydrophobic inter-
actions with Tyr-1766 in DIVS6.
The structures of several different bacterial voltage-gated
sodium channels (NavMs) are becoming available. Among
these, a newly available crystal structure confirms that cor-
responding residues align to form a transmembrane cavity
for hydrophobic blocking drugs. The channel includes
cavities (fenestrations) in the transmembrane region that
would allow access of hydrophobic ligands from the mem-
brane to enter the interior of the channel pore. Of impor-
tance, these fenestrations are much larger in the open than
in the closed state (8,9). The new structural information
supports previous findings that voltage-dependent confor-
mational changes of Nav1.4 may favor stronger interactions
with these residues and/or better positioning of the drug in
the channel pore (3).http://dx.doi.org/10.1016/j.bpj.2012.11.3830
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blockers is limited by such conformational variability and
docking energy studies of drug binding interactions for
LA-type drugs must necessarily consider the relevant state-
and use-dependent Nav channel conformations. Thus, clas-
sical structure-activity relationship studies still provide
key information for searching new promising Nav channel
blockers.
In an attempt to find potent use-dependent blockers of
Nav1.4 channels, we have previously screened several
newly synthesized analogs of the LA-like drugs Mex and
tocainide for their inhibitory action on native skeletal
muscle sodium currents, providing a foundation for subse-
quent docking energy studies to identify the molecular
determinants of drug action (10,11). We demonstrated
that replacement of the methyl group on the asymmetric
carbon atom with the lipophilic aromatic phenyl ring (as
shown for Me4, Fig.1) increased its potency for blocking
resting sodium channels by 10-fold (tonic block), but had
only a small effect on use-dependent block (UDB)
(12,13). A similar increase in potency was observed with
the concomitant presence of the phenyl group on the chiral
center and a single ortho-methyl group, with or withouta chlorine atom in para position, on the xylyloxy ring, sug-
gesting that this pharmacophore is important for proper
steric conformation of the drug and its interaction with
Nav (12,14). We also found that lengthening the amino-
alkyl chain to increase the distance between the chiral
carbon atom and the amino terminal group (as shown for
Me2, Fig. 1), decreased its potency in producing tonic
block (TB) of resting Nav1.4 and, importantly, produced
a corresponding increase in UDB (12–14). Whether this
increase is due to the change in physicochemical properties
such as pKa or the simple lengthening of the chain is not
yet established (15,16). However, an increase in UDB is
pivotal to the therapeutic usefulness of all LA-type
compounds in countering abnormal membrane hyperexcit-
ability (17).
This study builds on those findings and uses a panel of
newly synthesized LA-type compounds, together with
biophysical and molecular analysis of drug-channel interac-
tions, to define the structural requisites for drugs that
interact with the LA site on Nav1.4. We searched for novel
compounds in which the combination of favorable changes
at the main pharmacophores may increase both the potency
and use-dependent behavior on skeletal muscle sodiumFIGURE 1 Chemical structure of Mex and its
newly synthesized analogs. The boxes show the
compounds presently tested (continuous lines).
*Indicates the position of the chiral carbon atom.
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pharmacophore designed to evaluate:
1. the role of basicity and alkyl chain length in the use-
dependent behavior;
2. the role of the position of the stereogenic center of the
elongated alkyl chain in use-dependence and stereoselec-
tivity; and
3. the ability of combined modifications to the alkyl chain
or the aromatic ring to potentiate use-dependence and
stereo selectivity of phenyl derivative.
Biophysical interactions were assessed from measure-
ments of INa in adult single frog skeletal muscle fibers and
the experimental data were interpreted using ab initio
molecular modeling. In addition, studies on recombinant
human Nav1.4 and Nav1.5 were started to gain insight into
the tissue selectivity of the most potent compounds.MATERIALS AND METHODS
The screening of compounds on INa of single muscle fibers was carried out
by means of voltage-clamp recordings based on methods described by Hille
and Campbell (18) and detailed in the paragraph Additional Methods
section (in the Supporting Material) (19,20).Solutions and drugs
The compounds tested are shown in Fig. 1 (21). Chemical names and arbi-
trary abbreviated nomenclature are provided in the Additional Methods
section, along with the composition of solutions with and without drugs.Pulse protocols and analysis
The TB and UDB exerted by each compound was calculated as the percent
reduction of the maximal peak sodium transient (INa,max) elicited by depo-
larizing steps to 20 mV from the holding potential (HP) of 100 mV at
a frequency of 0.3 and 10 Hz, respectively. The use-dependent behavior
of test compounds was estimated by the further reduction of INa that
progressively increased above the TB in a frequency-dependent manner
until new steady-state amplitude was reached. The degree of UDB was
computed as the value of the steady-state INa,max at this point normalized
to the current at the same point in the absence of drug. This parameter
reflects the potency of the drug for blocking the channels under conditions
of high-frequency stimulation (i.e., as occurs during myotonic action poten-
tial firing). The voltage-dependent block was estimated with a pulse
protocol of infrequent depolarizing stimulation to 20mV for 10 ms
from two different HP values: very negative (140 mV), and depolarized
(70mV), resembling a pathological condition. As described previously,
this protocol reports drug binding to the channel in the inactivated and/or
the resting state, respectively (12,13). The concentration-dependence of
the drug effect was calculated as the half-maximal blocking concentration
(IC50) at 140 mV, which allowed calculation of the affinity constant for
the resting state (Kr). The IC50 value calculated from a HP of 70mV is
influenced both by the higher proportion of channels entering a closed-state
inactivation at this potential and by the possible ability of the drug, if acting
as an inactivated channel blocker, to modify this distribution in favor of
more inactivated channels. The affinity constant of the drug for the inacti-
vated channel (Ki) was computed using its voltage-dependent block, the
IC50 values, and the relative distribution of channels in the resting or inac-
tivated state obtained from the steady-state inactivation curve (22).Biophysical Journal 104(2) 344–354Molecular modeling
Molecular models of protonated R-Me1, R-Me4, S-Me12, and R-Me15
were constructed by fragments offered by the SPARTAN PRO (Wavefunc-
tion, Irvine, CA) inner fragment library and assuming the suggested default
starting geometries. Details of the ab initio molecular modeling are
described in the Additional Methods section.
Patch-clamp recordings
Sodium current measurement in HEK293 cells
Transient expression of cardiac channels was achieved by cotransfecting
human embryonic kidney (HEK293) cells with 10 mg hNav1.5 plasmid
and 1 mg gene reporter CD8 using the calcium phosphate coprecipitation
method. Cells expressing the channel were identified with microbeads
coated with anti-CD8 antibody (Dynal, Invitrogen) and used for patch-
clamp experiments 24–72 h after transfection. Permanent expression of
hNav1.4 was obtained in HEK293 cells as previously described (23).
Sodium currents were recorded at room temperature (21–22C) by the
whole-cell patch-clamp method, using an Axopatch 1D amplifier (Molec-
ular Devices, Sunnyvale, CA) and a 12-bit A-D/D-A interface (Digidata
1440A, Molecular Devices). Voltage-clamp protocols and data acquisition
were performed with pClamp software (version 10.2, Molecular Devices).
Sodium currents were elicited by 25 ms-long depolarizing test pulses to
30 mV from the holding potential of 120 mV, at two stimulation
frequencies: 0.1-Hz to determine TB and 10-Hz to determine UDB. Results
were analyzed offline using Clampfit (PClamp package) and SigmaPlot
8.02 (Systat software GmbH, Erkrath, Germany).
Drugs and solutions
Composition of pipette and bath solutions is provided in the Additional
Methods section. The compounds S-Me12 and R-Me15 were solubilized
in dimeethyl sulfoxide (DMSO)-supplemented bath solution. The final
concentration of DMSO did not exceed 0.2% and had no effects on sodium
currents.
Data analysis and statistics
The data were expressed as mean5 SE. IC50 values in the various exper-
imental conditions were determined using a nonlinear least squares fit of
the concentration-response curves to the following logistic equation:
Effect ¼ 100/{1þ(K/[drug])n}, where Effect is the percentage change
of INa; 100 is the maximal percentage block of INa; K is IC50; n is the
logistic slope factor, and [drug] is the molar concentration of the compound
(12,14). The hN curves were fitted with a single Boltzmann function, and
the potential at which 50% of the sodium channels were inactivated (Vh1/2)
was calculated at the inflection point of the curves (12,19). Statistical signif-
icance of differences between couples mean values was estimated using an
unpaired Student’s t-test and considered significant for p < 0.02. Statistical
significance of differences in IC50 values5 SE obtained from the fit was
evaluated by a Student’s t-test, where the number of degrees of freedom
is equal to the total number of preparations used to determine each point
on the curve minus the number of means determining the curve minus
two for the free parameters (13).
RESULTS
Potency of the newly synthesized analogs
for tonic and UDB
Role of basicity versus alkyl chain length in the
use-dependence
As previously reported (13,14,24), the insertion of a methy-
lene moiety in the alkyl chain of Mex, as in Me2, increases
Novel Lead Use-Dependent Blockers of Nav1.4 347the use-dependent behavior for blocking INamax compared to
the parent compound (Fig. 1; Table 1), and this is explained
by an increased basicity (12–14). Thus, we evaluated
whether the change of a highly basic group in place of the
amino one of Mex may also increase its use-dependent
behavior. To this aim, we synthesized and tested the guanyl
derivative of Mex Me13. Guanidine (NH2C ¼ NHNH2) is
a strong base (pKa ¼ 13.6) (25) and the substitution of
the nitrogen atoms of guanidine with alkyls, as in the case
of Me13, is expected to render it at least as basic as
guanidine (26).
Me13 displayed increased potency in tonic and UDB
versus Mex, positioning itself in the same rank order of
use-dependence as Me2. In fact, Me13 was ~twofold more
potent than Mex in tonic and 10-Hz use-dependent block,TABLE 1 Concentrations for half-maximal TB and UDB of





R r TB/UDBIC50 (mM) 10Hz IC50 (mM)
RS-Mex 755 8 1 2 23.65 2.8 1 1 3
R-Mex 745 82a 315 8 2
S-Mex 127.05 2.8 325 7 4
R-Me9 94 5 8b 1 1 17.95 1.8 2 1 5
S-Me9 1045 17 18.75 1.8 6
RS-Me13 53.15 2.7e,f 1 12.55 1.2e,f 2 4
R-Me2 1755 7 1 2 245 8 2 1 7
S-Me2 1095 4 a 17.55 2.1 6
R-Me10 645 6c 1 1 6.95 0.5c 4 1 9
S-Me10 785 6 9.25 1.6 8
R-Me11 1155 12 1 2 19.55 2.8 4 2 6
S-Me11 59.15 0.4a,c 7.75 1.9a,c 8
RS-Me14 46.45 2.7e 2 27.85 5.2 1 2
R-Me14 49.95 7.5 1 30.95 8.4 2 2
S-Me14 34.65 3.4a,c 2 17.75 2.1a 2 2
R-Me4 12.05 0.5 7 1 3.45 0.6 10 1 4
S-Me4 10.15 0.8 3.15 0.5 3
R-Me12 13.25 0.9 7 1 2.95 0.1 16 2 4
S-Me12 10.55 0.5a 1.95 0.1a,d 5
R-Me15 13.65 0.9a,d 5 2 1.95 0.2a,d 16 6 7
S-Me15 34.350.7 10.85 1.6 3
Concentrations able to produce half-maximal response (IC50, mM) in
producing a TB and a UDB. The ratio between IC50 values during TB
and UDB (IC50 TB/IC50 UDB 10-Hz) is shown to allow an easier compar-
ison of the use-dependent behavior of each compound. The IC50 values
have been obtained during nonlinear least-square fit of the concentration-
response data to the logistic equation described in the Methods. The ratio
(R) between IC50 values of Mex and IC50 values of each compound, for
the TB and UDB, is also shown to better evaluate the relative potency
toward the parent compound. The eudismic ratio (r ¼ IC50 distomer/IC50
eutomer) is an index of stereoselectivity.
a, b, c, and d show the statistic significance by Student’s t distribution (for
P < 0.001 or less) as follows:
abetween the enantiomers of the same compound;
bR-Me9 vs. R-Mex;
cR-Me10 and S-Me11 vs. S-Me2;
dS-Me12 and R-Me15 vs. S-Me4;
eRS-Me13 and RS-Me14 vs. RS-Mex;
fRS-Me13 vs. RS-Me14.respectively (Table 1). In agreement with the increased
potency of this analog, the concentration-response curves
were left-shift compared to Mex for both tonic and 10-Hz
use-dependent block, respectively (Fig. S1 B). In particular,
Me13 showed a high use-dependent behavior, with a ratio
(IC50 TB/IC50 10-Hz UDB) of 4, which correlates with
a strong basicity; in fact, Me13 has a higher pKa value
(12.15 5 0.70) than Mex (9.28 5 0.01) (Table S1).
However, further elongation of the intermediate alkyl chain
by formal insertion of a methylene group in the structure
of Me13 to obtain Me14 did not further increase its
potency in UDB, despite the stronger basicity of Me14
(Table S1). In fact, the dose-response curves describing
the TB by Me14 and Me13 were almost overlapping,
whereas that describing the UDB by Me14 at 10-Hz was
shifted to the right compared to those of Mex and Me13
(Fig. S1 B).
This finding suggests that Me14 displaces its main
pharmacophoric elements (i.e., the aromatic ring and the
charged group) in a manner that does not fit the steric
requirements of the receptor site on the sodium channel.
The guanidinium ion is a highly symmetric, planar Y-delo-
calized system that presents a distributed cationic charge
roughly centered on its iminic carbon atom. Consequently,
as can be seen in Fig S2 the distance between the cationic
charge and the aromatic ring in Me13 approximates that
of Mex homolog Me2, although the two groups are far
apart in Me14. This finding supports the idea that the
physicochemical properties that are pivotal for use-depen-
dent behavior are secondary to the structural requirements
that control drug interaction with the main residues of the
receptor site.
Role of the position of the stereogenic center in the optimal
alkyl chain length
With respect to the optimal length of the alkyl chain, we
evaluated whether the position of its asymmetric center
with respect to the main pharmacophore groups may also
play a role. The presence of a chiral center near the amino
terminal group (Me10) or near the aromatic aryloxy ring
(Me11), increased the potency for producing a TB of INa,
compared to Me2. As seen in Fig. S3 A, 10 mM of the euto-
mers R-Me10 and S-Me11 produced a TB (175 4%, n ¼ 3
and 20 5 5%, n ¼ 4, respectively) greater than that
observed with the same concentration of S-Me2 (6 5 7%,
n ¼ 4). Accordingly, the concentration-response curves
were left-shifted (Fig. S3 B). The relative IC50 values of
R-Me10, S-Me11, and R-Mex were lower compared to
that of S-Me2, and the increased potency was not due to
an increase in logP (Table S1). Both homologs Me10 and
Me11 showed a strong UDB behavior. In fact, the concen-
tration-response curves obtained after a train of depolarizing
pulses at 10-Hz were markedly left-shifted compared to
those of both Mex and Me2 Fig. S3 B. The eutomer
R-Me10, showed the greatest UDB behavior with a ratioBiophysical Journal 104(2) 344–354
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S-Me11, respectively (Table 1). Collectively, these results
suggest that the higher UDB of these two analogs
is explained by their higher estimated pKa values compared
to Me2 and especially to Mex. However, the finding
that the higher use-dependence of block by Me10 versus
Me11 is not associated with a further increase in pKa
(Table S1) suggests that more specific chemical interactions
between Me10 and the receptor site contribute to its
potency during frequency-dependent channel transitions.
In parallel, the presence of the asymmetric center near the
xylyloxy moiety as in Me11 increased its stereoselective
interaction versus Me2 and Me10, both during tonic and
phasic block, the eudismic ratio (r) being 2 and 3, respec-
tively (Table 1).
To better understand the impact of the chirality center
in the alkyl chain on stereoselectivity, we evaluated the
effects of Me9, a Mex analog in which the chirality
center is nearer to the aromatic xylyloxy ring (Fig. 1). It
is noteworthy that this latter change showed almost no
stereoselectivity for both TB and UDB, in parallel with
a less pronounced use-dependent behavior, compared to
its homolog Me2 (Table 1). This finding again suggests
that the optimal alkyl chain length must be maintained for
allowing combined or individual control of other drug
properties.
Effects of combined modifications on alkyl chain or xylyloxy
moiety in potent Me4 derivatives
As reported, the replacement of the methyl group on the
stereogenic center with the lipophilic aromatic phenyl
group, as in Me4, markedly increased its potency for
producing TB of INamax (12,13). The results described in
the previous paragraph indicate Me10 as the ideal use-
dependent long-chain analog to evaluate the effect of
combining the two modifications (Me12, Fig. 1). Interest-
ingly, the combined presence of the phenyl ring and the
long chain did not cause any remarkable change in the
potency of the drug for TB of INa compared to S-Me4,
the IC50 value being 10.5 5 0.5 mM for the eutomer
S-Me12 (Table 1, Fig. 2 A). Accordingly, the concentra-
tion-response curves for TB of S-Me4 and S-Me12 were
almost overlapping both being significantly shifted to the
left with respect to that R-Mex (Fig. 2 B). Of importance,
S-Me12 showed a higher use-dependent behavior than
S-Me4, the IC50 at 10-Hz being ~twofold lower than that
of Me4 and up to 16-fold lower than that of Mex (Table
1; Fig. 2 B). This high use-dependent behavior is consistent
with the increase in basicity expected from lengthening
the alkyl chain; in fact Me12 has a higher pKa value
(8.605 0.01) than Me4 (7.895 0.03) (Table S1). Interest-
ingly, Me12 also had a fourfold greater use-dependent
behavior compared to its parent compound Me10. This
increase is correlated in a more complex manner with phys-
icochemical properties and might be attributable to theBiophysical Journal 104(2) 344–354ideal logD value plus the pivotal role played by the chain
length (Table S1).
In parallel, we investigated the impact on Me4 of struc-
tural changes on the xylyloxy ring pharmacophore, based
on our previous demonstration that modifications at this
level may improve drug potency (14). The introduction of
a fluorine atom in the para position of the aromatic ring
with the concomitant removal of the one of the two
orthol-methyl groups, as in Me15, did not cause any remark-
able change in its potency compared to S-Me12, despite its
relatively modesty basicity. On the other hand, Me15
showed the high stereoselective behavior that was particu-
larly evident during high frequency stimulation. This trend
is clearly evident in the left-shift of the concentration
response curve of the R-enantiomer versus. the S-one
(Fig. 2 C). In particular, the eudismic ratio [IC50 distomer/
IC50 eutomer] was 6 (Table 1), the highest we have ever
found with this class of compounds. The latter observation
provides compelling evidence for a strong interaction
between the aromatic ring, less symmetrically substituted
in R-Me15 than in S-Me12 with its binding site, and that
this interaction is able to drive a conformational steric
disposition of the other pharmacophore at its site of
interaction.Voltage-dependent block and effects of the Mex
derivatives on steady-state inactivation of NaD
channels
We investigated the channel state-dependent affinity of the
various analogs. For each compound, we constructed
concentration-response curves for the block produced at
two different HP, 140 and 70 mV, in conditions of
low-frequency stimulation (Fig. S4). The scale of the
potency of the compounds for binding the resting channels
(Kr), evaluated at a HP of 140 mV was the same as
that found for TB at 100 mV, being Me15RMe12>
Me14>Me13>Me11>Me10 (Table 2). As expected
from inactivated channel blockers, an increased potency
was observed when the membrane potential was held at
70 mV, at which about half of the sodium channels
directly transit from the closed to the inactivated state. In
fact, the concentration-response curves of all compounds
were clearly shifted to the left with respect to those obtained
at 140 mV. The gain of potency for each compound at
the more depolarized potential ranged between 2- and
10-fold, with Me12 and Me15 again showing the highest
gain of potency. The order of potency was similar to
that found for the UDB at 10-Hz. Their affinity for the
inactivated state was calculated from the values of Kr and
K70, and confirms the high affinity of S-Me12 as an
inactivated channel blocker with affinity as low as 1.2 mM
(Table 2).
All the test compounds produced a significant and
concentration-dependent shift of the hN curves toward
FIGURE 2 Evaluation of the tonic and use-dependent block exerted by analogs S-Me4, S-Me12, and R-Me15. Upper panel A: are showing traces of INa
transients recorded in the absence and presence of drug. In each group of traces, the greatest one has been recorded in the absence of drug, with a depolarizing
step from the HP of 100 to 20 mV for10 ms. A similar depolarizing stimulus applied after the application of each compound allowed to estimate the
TB exerted by the drug (middle traces). The smallest current traces correspond to the residual current at the end of the 10-Hz stimulation protocol. The
INa reduction exerted by increasing drug concentrations and evaluated on the first-pulse trace and on the residual steady-state current allowed to construct
the dose-response curves for TB and UDB at 10-Hz (lower panel B). Lower panel C: are showing concentration-response curves for TB and 10-Hz UDB of
Naþ currents obtained with enantiomers of Me4 and Me15. The curves fitting the experimental points were obtained using the logistic function described in
Materials and Methods. Each value is the mean5 SE from 4 to 8 fibers of the percent block of INa observed in the presence of each concentration of drugs
versus INa in the absence of the drug in the same fiber.
Novel Lead Use-Dependent Blockers of Nav1.4 349more negative potentials, with a potency related to
their ability to block peak INa. Among the homologs, the
isomer S-Me12, which was the most potent in blockingsodium channels, was also the most effective in shift-
ing the hN curves toward more negative potentials
(Fig. S5).Biophysical Journal 104(2) 344–354
TABLE 2 Voltage-dependent block of sodium currents by
chiral analogs of Mex
Drug
Voltage-dependent block Inactivated state block
HP 140 mV HP 70 mV
Calculated Ki (mM)IC50 (mM); Kr IC50 (mM); K-70
R-Me10 1175 4 14.25 1.2 11.8
S-Me11 825 12 6.8 5 1.2 5.5
S-Me12 13.15 0.4 1.3 5 0.1 1.2
RS-Me13 685 3 31.75 0.4 28.6
RS-Me14 56 5 7. 21.55 0.4 18.8
R-Me15 12.85 1.7 1.2 5 0.3 1.9
Abbreviations: HP, holding potentials; IC50, half-maximal blocking
concentration; Ki, affinity constant for the inactivated state; Kr, affinity
constant for the resting state.
The columns from left to right are as follows: drug used; IC50 values at two
different HP values:140 and70mV; inactivated-state block refers to the
affinity constants for inactivated sodium channels (Ki) according to the
equation in Materials and Methods.
350 De Bellis et al.Ab initio molecular modeling of Me12
or Me15 vs. Me4
Why does S-Me12 have the same activity as its inferior
homologs R- and S-Me4?
The longer alkyl chain of Me12 versus Me4 increased its
use-dependent behavior but did not alter its potency in
exerting a TB. To further understand the molecular bases
for this difference, we undertook an ab initio molecular
modeling study of S-Me12—the eutomer of Me12—and
R-Me4. These enantiomers were chosen based on the lack
of stereoselectivity of Me4 during UDB and the observation
that, despite its stereochemical descriptor, S-Me12 shares
the same configuration as R-Me4. The HF/6-31G**//HF/3-
21G* most stable conformers of these compounds are
shown in Fig. S6. Despite homologation, both compounds
place their main pharmacophoric elements—the protonated
amino group and the xylyloxy ring—at the same distance
(5.18 5 0.07 A˚, measured from the charged nitrogen
atom to the phenyl ring centroid). It is likely that an intra-
molecular hydrogen bond contributes to conformer stabili-
zation, this interaction being tighter for S-Me12 than
R-Me4 as reflected by the distance between H and O
atoms—the donated and accepting atoms in the hydrogen
bonds (1.61 A˚ and 1.83 A˚, respectively) (Fig. S6). In line
with this observation, the most positive electrostatic
potential located near the protonated nitrogen atom was
lower for S-Me12 than for R-Me4 (154.7 Kcal/mol and
164.4 Kcal/mol, respectively) (Fig. S6), reflecting higher
delocalization of the positive charge through hydrogen
bonding for S-Me12. Interestingly, the number of HF/6-
31G**//HF/3-21G* stable conformations falling in the
window of 5 Kcal/mol over the global minimum conformer
was lower for S-Me12 than R-Me4 (2 and 4, respectively),
although the superior homolog has one more rotatable
bond. This observation may reflect a higher constraint forBiophysical Journal 104(2) 344–354S-Me12 than R-Me4, possibly explaining the higher eudis-
mic ratio found for the superior homolog of this pair of
enantiomers.
Why do changes at the xylyloxy ring in Me15 lead to high
potency and stereoselectivity vs. Me4?
The ab initio molecular modeling study on R-Me15 showed
the presence of two almost degenerate conformers as the
most stable ones at the HF/6-31G**//HF/3-21G* level
(Fig. 3, A and B): in conformer a (absolute minimum
conformer) the plane containing the aryloxy ring and the
one made by the ether functional group are almost orthog-
onal (synclinal, dihedral angle: –81); whereas, in conformer
b (less stable for only 0.3 Kcal/mol) the two planes are syn-
periplanar (dihedral angle: –25). Thus, rotation around the
Car-O bond is less hindered in R-Me15 than in R-Me4,
which presents only an orthogonal disposition of these
planes for all conformers within the window of 5 Kcal/mol
over the global minimum. The electrostatic potential map
for the most stable HF/6-31G**//HF/3-21G* conformer of
R-Me15 (Fig. 3 C) demonstrates that, due to the strong elec-
tron withdrawing effect of the fluorine atom, the electronic
distribution on the aromatic ring is quite different from the
one observed in R-Me4, with most of the electron negative
charge concentrating on the halogen atom. Taken together,
the observed reduction of both electron density of the
aromatic ring and steric hindrance around the CAr-O
bond should favor delocalization of the oxygen lone pairs
and polarizability of the aromatic moiety. Interestingly,
by performing the same molecular modeling study on the
chlorine isologue R-Me1 (14), a synperiplanar conformer
was found only at 1.8 Kcal/mol over the global minimum
conformer (data not shown). This finding supports a role
of the electron withdrawing effect of the fluorine atom in
determining the ring plane orientation.
The results of this modeling analysis predict the experi-
mental data well. In fact, despite its relatively modest
basicity, R-Me15 was as potent as S-Me12 and also had
the highest eudismic ratio in the series. The latter observa-
tion supports the involvement of a strong interaction
between the aromatic rings, less symmetrically substituted
in R-Me15 than in S-Me12, with its binding site. The high
stereoselectivity observed does support the role of the ary-
loxy moiety as a pharmacophoric element able to condition
the interaction of the main pharmacophoric group—the
protonated amine—with its binding site. In particular, the
fluorine atom, which is highly electron dense in the Me15
molecule, in addition to contributing to the disposition of
the CAr-O bond, may confer stronger electronic effects,
hydrogen bonds, and halogen bonds than the xylyloxy rings
without alogens or with a chlorine substituent.
Muscle versus cardiac effect of most potent derivatives
Based on these results, we undertook an initial investigation
of the specificity of the two most potent derivatives, S-Me12
FIGURE 3 (A) The two most stable conformers of Me15—a, synclinal,
and b, synperiplanar; dihedral angles between the aromatic ring and ether
functional group containing planes are highlighted. (B) Newman projec-
tions obtained observing a and b from the fluorine atom side in the direction
of the bond connecting the latter to the aryloxy ring (for the sake of
simplicity hydrogen atoms have been omitted). (C) Electrostatic potential
maps for R-Me15 and R-Me4.
Novel Lead Use-Dependent Blockers of Nav1.4 351and R-Me15, for skeletal compared to cardiac muscle
sodium channels. The two compounds were tested at a single
concentration of 10 mM, close to the half-maximal one, on
hNav1.4 and hNav1.5 channels expressed permanently or
transiently, respectively, in HEK293 cells. INa was recorded
in the whole-cell patch-clamp configuration. Both TB and
UDB were estimated under conditions of low (0.1-Hz) andhigh (10-Hz) frequency of stimulation from the holding
potential of 120 mV to 30 mV. Fig. S7 shows represen-
tative traces of sodium currents recorded before (CTRL) and
after application of drug (10 mM). Both compounds were
~10-fold more potent than Mex in producing TB of
hNav1.4 and hNav1.5; their TB at 10 mM was comparable
or greater than that observed with 100 mM Mex (27,28).
As seen in Fig.S7, S-Me12 was more effective in blocking
hNav1.5 than hNav1.4 at low stimulation frequencies, with
a calculated specificity ratio (block Nav1.5/block Nav1.4)
of 2.6-fold. A similar result was found for R-Me15 (ratio
4). However, consistent with results on native myofibers,
S-Me12 exhibited a high use-dependence on hNav1.4. In
particular, S-Me12 had a twofold greater use-dependence
on hNav1.4 compared to hNav1.5, becoming equipotent
on both channel types (ratio ¼ 1), whereas R-Me15 was
less use dependent. Therefore, the newly synthesized
compounds, although more potent than Mex in absolute
terms, did not show any specific advantage in channel
subtype specificity. Their apparent greater affinity for heart
over skeletal muscle compared to Mex can be explained by
both compounds being high-affinity inactivated channel
blockers in combination with the different biophysical
profile of the channel isoforms. In fact, the inactivated state
is more favored for heart compared to skeletal muscle
channel subtypes.DISCUSSION
Understanding the complex molecular interactions that
underlie UDB of Nav channels by drugs is important for
a more complete understanding of Nav structure-function
relationships as well as for the rational design of therapeutic
compounds for treating membrane disorders of hyperexcit-
ability. The voltage-gated sodium channels represent an
important therapeutic target for the development of drugs
useful in the treatment of many diseases in which the
channel may be directly or indirectly involved (1,29).
Current private research in the pharmaceutical industry is
mainly focused on identifying sodium channel blockers
that may have therapeutic application in widespread patho-
logical conditions such as neuropathic pain (30,31). There is
much less research on the development of blockers that
target Nav subtypes relevant to the more rare human disor-
ders such as myotonic syndromes and periodic paralyses
(1). In parallel, various academic groups are involved in
site-directed mutagenesis and molecular biology combined
with biophysical studies aimed at further understanding
the molecular mechanisms that underlie drug-receptor inter-
actions and the molecular determinants for tissue selectivity
(3,8,32). Only limited published information is available on
the structural determinants for potent and use-dependent
modulation of voltage-gated sodium channels, also because
the structures of the most potent compounds are undisclosed
or patent-covered before reaching the market.Biophysical Journal 104(2) 344–354
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many years to characterizing the molecular determinants
of LA-like drugs; the rational design of new sodium channel
blockers that can be safely used to treat excitability distur-
bances in patients affected by the drug-orphan skeletal
muscle channelopathies (1). Our studies have provided
key information about structural requirements and then a
concrete contribution to facilitate, in a larger context, the
development of new molecules of potential clinical interest.
Our previous studies showed that the activity of Mex-like
sodium channel blockers is strongly modulated by the part
of the molecule near the asymmetric carbon atom. In fact,
the presence of a lipophilic moiety such as a phenyl group
on the chiral center enhances its potency up to 10-fold
(12,13). Lengthening the alkyl chain in association with
increased basicity increases the use-dependent behavior
(12–14). These structural modifications improved the anti-
myotonic activity, evaluated in vitro and in vivo as the
ability to counteract myotonic symptoms in the myotonic
adr/adr mouse (20,33). On the basis of these findings, and
with the dual aim of improving the therapeutic profile and
gaining more insight in structural determinants for drug
action, we further investigated the role of basicity in the
use-dependent behavior. It is well accepted that most of
the use-dependency derives from the quota of charged mole-
cules reaching the local-anesthetic binding site (1). It has
been recently shown that the experimentally derived pKa
value of Mex is 9.28 (21); therefore, Mex is expected to
be 99% ionized at physiological pH. In principle, further
increasing its basicity should not enhance its use-depen-
dence. However, charged species experience a lower dielec-
tric environment in the channel pore than in bulk solution
and this reduces their effective pKa once in the membrane
interior (34). In other words, when interacting with its
target, Mex behaves as a weaker base than what may be
anticipated on the basis of its experimentally derived pKa
(35). Consequently, Mex analogs designed to be more basic
than the reference compound might display a more favor-
able blocking activity profile. In agreement with this view,
we have shown that the presence of a guanidinum group
(Me13) increases both its pKa and use-dependent behavior.
This compound shows a profile similar to the elongated
chain homolog Me2, which also has a higher pKa than
Mex. On the other hand, further elongation of the alkyl
chain of Me13, as done in Me14, did not further potentiate
its UDB, despite the stronger basicity of Me14. These obser-
vations are in agreement with previous reports showing
the importance of both basicity and optimal alkyl chain
length per se for sodium channel blocking compounds
(13,21,24,36,37). As shown in Fig. S2, the distance between
the cationic charge and the aromatic ring in Me13 is greater
than that in Mex while approximating that for Mex homo-
logs (e.g., Me2,) and being shorter than that of the less effec-
tive Me14. These results underscore the importance of an
optimal alkyl chain length and a basic pKa for use-depen-Biophysical Journal 104(2) 344–354dent behavior. These observations support the importance
of a basic pKa for a use-dependent behavior as secondary
requirements versus structural backbone that controls drug
interaction with main residues. In this respect, the asym-
metric center can also play a pivotal role. Me10 and
Me11, in which the chirality center in the elongated alkyl
chain is adjacent to the main pharmacophore groups (i.e.,
the amino terminal group or the aromatic xylyloxy ring,
respectively) were approximately twice as potent in deter-
mining TB as Me2. This behavior can be explained by
a greater flexibility of the alkyl chain due to the noncentral
position of the asymmetric center, thereby ensuring an
optimal conformation for interaction with the binding site,
as suggested by Sheldon et al. (1991) (36). This view is
also supported by the hypothesis of vertical orientation of
the drug in the open channel (3). Accordingly, the longer
alkyl chain in Me10 increases its use-dependence and can
again be explained by a general higher basicity that
enhances its interaction with the binding site. The gain of
potency of Me10 in high-frequency stimulation conditions
supports its potential interest as a lead compound for
controlling hyperexcitability disorders such as myotonia.
Me10 may also have pharmacokinetic advantages in that
its structure is expected to be less liable to metabolic oxida-
tive deamination in vivo than Me11 (21).
These considerations led us to test whether the combina-
tion of the homologated alkyl chain with the phenyl moiety
on the asymmetric center (Me12) may enhance the use-
dependent interaction of LA-type drugs with Nav channel.
This combination of structural requirements did not signif-
icantly change the potency for TB of INa but significantly
enhanced UDB (e.g., when the phenyl derivative and short
alkyl chain were combined in Me4). Although the increase
in pKa can again account for the increased use-dependence,
molecular modeling helped us to gain insight in the similar
potency of Me12 vs. Me4. Despite homologation, both
compounds place their main pharmacophoric elements—
the protonated amino group and the aryloxy ring—at the
same distance, whereas an intramolecular hydrogen bond
contributes to tighter conformer stabilization for Me12
than Me4.
An important remaining question is whether it is possible
to further enhance the potency of LA-like compounds on the
Nav1.4 channel by the use of enantiomers. Pure enantiomers
may be clinically useful due to enantioselective metabolism
and the possible presence in vivo of active stereoselective
metabolites (38,39). Although residues potentially involved
in a stereoselective three point interaction of LA-type drugs
with the sodium channel have been described, stereoselec-
tivity of sodium channel blockers in various tissues is rather
modest (40). A limited stereoselective block of sodium
channels also occurs in skeletal muscle (12,15). However,
the structural requirements for stereoselectivity in blocking
channels are not fully known. Interestingly, in this work, we
observed that the compound in which the asymmetric center
Novel Lead Use-Dependent Blockers of Nav1.4 353is nearby to the xylyloxy ring (Me11) and one in which an
o-methyl was removed and a fluorine atom was introduced
in the 4-position of the aromatic ring (Me15) showed the
highest degree of stereoselectivity. It is likely that, in
Me11, the methyl substituent tunes the orientation of the
xylyloxy ring and constrains it by steric hindrance through
intramolecular bonding. Accordingly, previous studies
using tocainide analogs in which the chiral center is con-
strained into a rigid proline cycle are those showing the
greatest stereoseletive behavior to date (15).
The greater stereoselectivity of Me15 may have a more
complex explanation, because the main structural changes
are present at the level of the xylyloxy ring, rather far
from the chirality center.
It is generally accepted that the aromatic ring of Mex and
analogs interacts with the Nav channel at IVS6-Tyr (5,10).
However, elegant site-directed mutagenesis studies by
Ahern et al. (2) demonstrated that the interaction of LA
and its quaternary ammonium derivative QX-130 with
IVS6-Tyr is not an aromatic-aromatic one, supporting
previous observations by Courtney and Strichartz (35).
The latter authors suggested that the ring acts more as an
aliphatic than an aromatic group, due to the ability of the
o-methyl groups to force the carboxamide group to a direc-
tion perpendicular to the plane of the aromatic ring, thereby
producing a resonance decoupling effect. On the basis of the
previous results, Fozzard et al. (4) have recently concluded
that an aliphatic interaction of the aromatic moiety of local
anesthetics with IVS6-Tyr plays a secondary role in the
drug-receptor interaction. Their study reinforces the view
that the main electrostatic interaction of the charged amino
group is with IVS6-Phe and that IVS6-Tyr plays only
a secondary role. However, our recent results obtained
with a series of Mex analogs require the role of the xylyloxy
in the interaction with the binding site to be reconsidered
(28). In particular, the introduction of hydroxyl groups
onto the xylyloxy moiety of mexiletine modifies the
high-affinity binding of the protonated amine terminal to
IVS6-Phe through a cooperativity between the two pharma-
cophore groups, and mutation of IVS6-Tyr further impairs
such cooperativity (28). These observations are consistent
with the previous finding, obtained using a series of phenyl
analogs of Mex, that the introduction of a chlorine atom
in the 4-position of the xylyloxy ring along with the
replacement of an o-methyl group increases drug potency
and inverts stereoselectivity. This finding first suggested
a possible relationship between the site of interaction of
the protonated amino group on the stereogenic center and
the aromatic moiety interaction site (12). Thus, we specu-
lated that Mex analogs may have further interactions with
the IVS6-Tyr binding site beside the merely aliphatic one.
The current results obtained with enantiomers of Me15 in
which an o-methyl was removed and a fluorine atom was
introduced in the 4-position of the aromatic ring, favor these
putative interactions. Such interactions are further supportedby molecular modeling. The disruption of symmetry at the
xylyloxy ring reduces steric hindrance, thus allowing reso-
nance between the lone pairs of the oxygen atom and the
aromatic sextet. In addition, the introduction of a fluorine
atom in the para position reduces the electron density of
the aromatic ring thus making it complimentary to the
supposed electron rich ring of IVS6-Tyr. Furthermore, the
electron dense fluorine atom may confer additional
hydrogen and/or halogen bonding interactions (41). Accord-
ingly, the analysis of conformers confirmed that the rotation
around the CAr-O bond is less hindered in R-Me15 than in
R-Me4, the latter presenting only an orthogonal disposition
compared to a higher number of more planar conformers of
Me15. Together, these considerations suggest the occurrence
of a strong interaction of the less symmetrically substituted
aromatic ring of R-Me15, with its Tyr binding site which is
able to influence the interaction of the main pharmacophore
group—the protonated amine—with its binding site at the
Phe residue. Our current results provide new, to our knowl-
edge, insights into the relative role of pharmacophores for
binding to crucial residues on Nav and suggest novel lead
molecules for enhancing potency, use-dependence, and
stereo selective behavior. The new compounds may be help-
ful in future docking studies and energetic modeling, espe-
cially in relation to IVS6-Tyr binding.
Finally, our initial tests of the activity of the most potent
derivatives on recombinant human sodium channels confirm
the poor tissue selectivity of this class of compounds against
different Nav channel isoforms. Their modest differences in
potency against cardiac and skeletal muscle Nav channels is
most likely due to differences in state-dependent binding,
with the cardiac hNav1.5 channel having more resting inac-
tivation than the skeletal muscle hNav1.4 channel. Future
studies will be devoted to testing the most promising
analogs on other Nav isoforms, such as the CNS, to gain
further insight into their pharmacological profile. Neverthe-
less, because use-dependence properties selectively address
the activity of a compound against pathological conditions,
the new compounds Me10, Me12, and Me15 deserve further
investigation of their potency against membrane hyperexcit-
ability both in vitro and in vivo.Policy and ethics
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